Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5

WILMINGTON, Del. and SACRAMENTO, Calif., Aug. 27, 2026 — Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today announced the filing of its Second Amended Complaint naming six registered broker-dealers and two broker-dealer principals as defendants for the first time, in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC).

A copy of the Second Amended Complaint is available at https://bit.ly/45Q1MLE.

About Lunai Bioworks, Inc.

Lunai Bioworks, Inc. (Nasdaq: LNAI) is a Delaware corporation headquartered in Sacramento, California. Lunai is an AI-driven platform for precision medicine that identifies targets for new therapeutics and biodefense countermeasures. The company has developed a cancer immunotherapy for solid tumors and proprietary, patented technologies that transform complex biomedical data into predictive insights. Lunai's platforms include Augusta, an AI-powered precision neurology platform, and a portfolio focused on central nervous system disorders. The company also pursues federal government contracts in support of national security and biodefense applications through its AI platform. For more information, visit www.biosymetrics.com.